Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe?

Inflammation Research

Volumn 58, Issue 6, 2009, Pages 292-297

  Kilic D ^a   Gunaydin, S ^a   Kisa, U ^a   Sari, T ^b   Deveci, O ^a   Zorlutuna, Y ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b BAYINDIR HOSPITAL   (Turkey)

Author keywords

Biocompatible; Cardiopulmonary bypass; Coated materials; Leukapheresis; Leukocyte Filtration; Reperfusion injury; Surface Modifying Additives

Indexed keywords

CREATINE KINASE; D DIMER; GELATINASE B; HEPARIN; INDICATOR; MACROGOL; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLAMP; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY SINUS; EXTRACORPOREAL CIRCULATION; FILTERING OPERATION; FILTRATION; HEART MUSCLE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LEUKOCYTE; LEUKOCYTE FILTRATION; RISK ASSESSMENT; THYROXINE BLOOD LEVEL;

EID: 67649532294     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-7244-1     Document Type: Article

References (25)

1. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37:171-185
2. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75:S715-S720
3. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecues. Ann Thorac Surg 1998; 66:2135-2144.
4. Samankatiwat P, Samartzis I, Lertsithichai P, Stefanou D, Punjabi PP, Taylor KM, et al. Leucocyte depletion in cardiopulmonary bypass: a comparison of four strategies. Perfusion 2003; 18(2): 95 -105.
5. Gunaydin S, McCusker K, Vijay V, Sari T, Sargon MF, et al. Clinical evaluation strategic leukofiltration with surface modification: Enhanced preservation or fantasy. Filtration 2005; 1(1):57-67
6. Sheppard SV, Gibbs RV, Smith DC Does leucocyte depletion during cardiopulmonary bypass improve oxygenation indices in patients with mild lung dysfunction? Br J Anaesth 2004; 93(6):789-792.
7. Ortolano GA, Aldea GS, Lilly K, O'Gara P, Alkon JD, Mader F, et al. A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects. Perfusion 2002; 17: S53-S62.
8. Toumpoulis IK, Anagnostopoulos CE, Swistel DG, DeRose JJ Jr. Does EuroSCORE predict length of stay and specific postoperative complications after cardiac surgery? Eur J Cardiothorac Surg. 2005; 27(1):128-133.
9. Tayama E, Hayashida N, Akasu , Kosuga T, Fukunaga S, Akashi H, et al. Biocompatibility of heparin coated extracorporeal bypass circuits: New heparin bonded bioline system. Artificial Organs 2000; 24(8): 618-623.
10. Colman RW. Hemostatic complications of cardiopulmonary bypass. Am J Hematol. 1995; 48(4):267- 272.
11. Taylor KM. SIRS-the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61(6): 1607- 1608.
12. Asimakopoulos G. The inflammatory response to CPB: the role of leukocyte filtration. Perfusion 2002; 17 Suppl: 7-10.
13. Falagas ME, Rosmarakis ES, Rellos K, Michalopoulos A, Samonis G, Prapas SN. Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopul-monary bypass. J Thorac Cardiovasc Surg 2006; 132(3): 481 -490.
14. Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993; 164:193-202
15. Kozik JD, Tweddell JS. Characterizing theinflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006; 81:S2347-S2354
16. Baksaas ST, Flom-Halvorsen HI, Ovrum E, et al. Leucocyte filtration during cardiopulmonary reperfusion in coronary artery bypass surgery. Perfusion 1999; 14: 107-117
17. Gunaydin S, McCusker K, Vijay V. Strategic leukofiltration in cardiac surgery. Curr Med Chem-Cardiovascular & Hematologic Agents 2005; 3:173-179
18. Gunaydin S, McCusker K, Vijay V et al. Clinical significance of strategic leukocyte filtration in different risk cohorts undergoing cardiac surgery. Filtration 2005, 1(2):95 - 106.
19. Balci C, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7(1):85-90.
20. Mahoney CB. Heparin-bonded circuits: clinical outcomes and costs. Perfusion 1998; 13(3): 192-204.
21. Zimmermann AK, Aebert H, Reiz A, Freitag M, Husseini M, Ziemer G, Wendel HP. Hemocompatibility of PMEA coated oxygenators used for extracorporeal circulation procedures. ASAIO J 2004; 50(3): 193-199.
22. Hamada Y, Kawachi K, Nakata T, Kohtani T, Takano S, Tsunooka N. Antiinflammatory effect of heparin-coated circuits with leukocyte-depleting filters in coronary bypass surgery. Artif Organs 2001; 25:1004-1008.
23. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9-13
24. de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA, Hack CE, et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 2004; 98(6): 1586-1594.
25. Gunaydin S, Ayrancioglu K, Dikmen E et al. Clinical effects of leukofiltration and surface modification on post-cardiopulmonary bypass atrial fibrillation in different risk cohorts. Perfusion 2007, 22(4):279-88